| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00689702 |
| P698 | PubMed publication ID | 2060084 |
| P50 | author | Per Ljungman | Q52717443 |
| P2093 | author name string | M Hassan | |
| J Aschan | |||
| A Taube | |||
| H Ehrsson | |||
| I Wallin | |||
| G Lönnerholm | |||
| B Smedmyr | |||
| G Oberg | |||
| A N Bekassy | |||
| P2860 | cites work | Clinical pharmacokinetics-pharmacodynamics of anticancer drugs | Q38649105 |
| Pharmacokinetics of anticancer drugs in children | Q39768346 | ||
| Chronopharmacology | Q39820030 | ||
| Chronobiology: its importance in clinical medicine | Q39829593 | ||
| Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma | Q40585977 | ||
| Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children | Q41906112 | ||
| Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia | Q42261326 | ||
| Studies of the development of basic, neutral and acidic isoenzymes of glutathione S-transferase in human liver, adrenal, kidney and spleen | Q42564076 | ||
| Bleomycin disposition in children with cancer | Q42664850 | ||
| Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison | Q43598731 | ||
| Metabolism of 14C-busulfan in isolated perfused rat liver | Q43692742 | ||
| Circadian rhythm in tolerance of mice for etoposide | Q49029761 | ||
| Busulfan disposition in children | Q68759019 | ||
| Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation | Q69392787 | ||
| Paediatric drug dosing. Bodyweight versus surface area | Q69579988 | ||
| Pharmacokinetic and metabolic studies of high-dose busulphan in adults | Q69665196 | ||
| Pharmacokinetics of high-dose busulfan in children | Q69747732 | ||
| Circadian timing of cancer chemotherapy | Q69884877 | ||
| Gas chromatographic determination of busulfan in plasma with electron-capture detection | Q71104880 | ||
| Body water compartments in children: changes during growth and related changes in body composition | Q78841789 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 130-134 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology | |
| P478 | volume | 28 |
| Q44245108 | A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning |
| Q36166109 | A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patients |
| Q46138906 | Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant |
| Q41734536 | An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease |
| Q41178776 | Aspects concerning busulfan pharmacokinetics and bioavailability |
| Q44970619 | Busulfan and cycosporin in bone graft children |
| Q44110270 | Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation |
| Q70806164 | Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation |
| Q34668052 | Busulfan in hematopoietic stem cell transplantation |
| Q73101615 | Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia |
| Q40558164 | Busulfan. |
| Q43950778 | Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages |
| Q40625264 | Chronopharmacokinetics. Are they clinically relevant? |
| Q52552920 | Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. |
| Q30497854 | Clinical pharmacology in the adolescent oncology patient |
| Q45044487 | Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation |
| Q57906791 | Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection |
| Q45267594 | Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants |
| Q43848123 | Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation |
| Q46020728 | Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients. |
| Q47116870 | Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. |
| Q70997282 | Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy |
| Q70692212 | Gas-chromatographic analysis of busulfan for therapeutic drug monitoring |
| Q35561988 | Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment |
| Q44830422 | I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients |
| Q40667425 | Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens |
| Q44640634 | In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) |
| Q58788918 | Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning |
| Q43507901 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies |
| Q51676244 | Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. |
| Q51443713 | Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI. |
| Q57493528 | Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia |
| Q43690748 | Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation |
| Q33859991 | Oral chemotherapy agents in the treatment of leukaemia |
| Q41818881 | Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation |
| Q43583155 | Pharmacokinetics of liposomal busulphan in man. |
| Q41489633 | Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. |
| Q38060264 | Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. |
| Q34025212 | Plasma concentration monitoring of busulfan: does it improve clinical outcome? |
| Q86894224 | Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients |
| Q43796849 | Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients |
| Q53580759 | Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. |
| Q50802622 | Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q46884990 | Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation |
| Q39436393 | Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation |
| Q44419087 | Predictive performance of a physiologically based pharmacokinetic model of busulfan in children |
| Q61590906 | Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol |
| Q43800587 | Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children |
| Q51152596 | Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. |
| Q73375179 | Retrospective appraisal of busulfan dose adjustment in children |
| Q48239404 | Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. |
| Q28072227 | T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome |
| Q43848079 | Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation |
| Q47313046 | Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? |
| Q35062145 | The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine |
| Q44110264 | The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo |
| Q40789141 | The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro |
| Q28374416 | The role of busulfan in bone marrow transplantation |
| Q96127498 | UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring |
| Q73428190 | Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan |
| Q36792760 | Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients |
Search more.